On September 2, Shanghai Opmeg Biotechnology Co.
Huaxing's medical industry fund strategically invested in Oppler in 2018, which set the largest single financing record in the field of cell culture in China that year, and since then, it has used Huaxing's deep insight into the future development direction of its industry and the leading capital operation ability of China Renaissance Capital to help the company achieve multi-dimensional industrial integration such as technology and talents, complete Oppler's long-term strategic planning, and achieve the post-investment management goal
of releasing the company's growth potential.
Founded in 2013, Opmey is a high-tech enterprise specializing in cell culture products and services, focusing on the research and development and production of antibody and vaccine media, based on the concept of animal cell culture and the development experience of serum/chemical composition limited media process, has established a large-scale GMP-compliant media production base, developed a variety of media products that can replace imported brands confirmed by customers, and has achieved commercial sales, which are widely used in protein/antibody production, vaccine production, The field
of biological products production such as cell therapy and gene therapy.
While having high-quality media products, Opram has always been developing cell culture technology and processes, continuously optimizing the product quality of serum-free media to ultimately achieve rapid growth of cultured cells and high expression of
products.
Fan Bao, Chairman of China Renaissance Capital Group, Founding Partner and Chief Investment Officer of the Fund, said: "Congratulations to Oppmai! Over the past decade, Opmey has been committed to the localization of culture media and has developed the world's advanced, fully autonomous and controllable cell culture technology and a wide variety of cell culture media products
.
Zhang Junjie, founding partner of Huaxing Medical Industry Fund, said: "The development of China's biopharmaceutical industry is inseparable from the construction
of the entire industrial chain.
On September 2, Shanghai Opmeg Biotechnology Co.
Huaxing's medical industry fund strategically invested in Oppler in 2018, which set the largest single financing record in the field of cell culture in China that year, and since then, it has used Huaxing's deep insight into the future development direction of its industry and the leading capital operation ability of China Renaissance Capital to help the company achieve multi-dimensional industrial integration such as technology and talents, complete Oppler's long-term strategic planning, and achieve the post-investment management goal
of releasing the company's growth potential.
Founded in 2013, Opmey is a high-tech enterprise specializing in cell culture products and services, focusing on the research and development and production of antibody and vaccine media, based on the concept of animal cell culture and the development experience of serum/chemical composition limited media process, has established a large-scale GMP-compliant media production base, developed a variety of media products that can replace imported brands confirmed by customers, and has achieved commercial sales, which are widely used in protein/antibody production, vaccine production, The field
of biological products production such as cell therapy and gene therapy.
While having high-quality media products, Opram has always been developing cell culture technology and processes, continuously optimizing the product quality of serum-free media to ultimately achieve rapid growth of cultured cells and high expression of
products.
Fan Bao, Chairman of China Renaissance Capital Group, Founding Partner and Chief Investment Officer of the Fund, said: "Congratulations to Oppmai! Over the past decade, Opmey has been committed to the localization of culture media and has developed the world's advanced, fully autonomous and controllable cell culture technology and a wide variety of cell culture media products
.
Zhang Junjie, founding partner of Huaxing Medical Industry Fund, said: "The development of China's biopharmaceutical industry is inseparable from the construction
of the entire industrial chain.
On September 2, Shanghai Opmeg Biotechnology Co.
Huaxing's medical industry fund strategically invested in Oppler in 2018, which set the largest single financing record in the field of cell culture in China that year, and since then, it has used Huaxing's deep insight into the future development direction of its industry and the leading capital operation ability of China Renaissance Capital to help the company achieve multi-dimensional industrial integration such as technology and talents, complete Oppler's long-term strategic planning, and achieve the post-investment management goal
of releasing the company's growth potential.
Founded in 2013, Opmey is a high-tech enterprise specializing in cell culture products and services, focusing on the research and development and production of antibody and vaccine media, based on the concept of animal cell culture and the development experience of serum/chemical composition limited media process, has established a large-scale GMP-compliant media production base, developed a variety of media products that can replace imported brands confirmed by customers, and has achieved commercial sales, which are widely used in protein/antibody production, vaccine production, The field
of biological products production such as cell therapy and gene therapy.
While having high-quality media products, Opram has always been developing cell culture technology and processes, continuously optimizing the product quality of serum-free media to ultimately achieve rapid growth of cultured cells and high expression of
products.
Fan Bao, Chairman of China Renaissance Capital Group, Founding Partner and Chief Investment Officer of the Fund, said: "Congratulations to Oppmai! Over the past decade, Opmey has been committed to the localization of culture media and has developed the world's advanced, fully autonomous and controllable cell culture technology and a wide variety of cell culture media products
.
We believe that Oppler will be able to seize the basic soil opportunities of cell culture by virtue of its R&D strength and growth potential in the capital market, and grow into a leading enterprise
in the field of domestic culture media.
Huaxing will also continue to support enterprises, build national high-quality brands, and assist companies to actively explore overseas markets and realize the overseas
development of domestic brands.
”
Zhang Junjie, founding partner of Huaxing Medical Industry Fund, said: "The development of China's biopharmaceutical industry is inseparable from the construction
of the entire industrial chain.
Through the business model of organic integration of culture media + CDMO, Opmeg reduces the production cost of antibody drugs with high-quality media, realizes import substitution, and empowers innovative drug development
with a one-stop CDMO platform.
Over the past five years, we have accompanied the company and supported the company to achieve continuous breakthroughs in technology, continuous extension of business and rapid growth of the
team.
We expect that under the leadership of Dr.
Xiao, Oppler will create greater value for customers, not only to help the long-term development of China's biopharmaceutical industry, but also to become an international leading enterprise
in the biopharmaceutical industry chain.
" ”
